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A series of arylpiperazine derivatives of hydantoin-3-acetate, including previously obtained
5,5-diphenylhydantoin (1–7) and new-synthesized spirofluorene-hydantoin derivatives (8–12), were
investigated in the search for new inhibitors of the tumour multidrug resistance (MDR) efflux pump
P-glycoprotein (P-gp, ABCB1) overexpressed in mouse T-lymphoma cells. Synthesis of new compounds
(8–12) was performed. Crystal structures of two compounds (8 and 11) were determined by X-ray
diffraction method. The conformations of the investigated molecules (8 and 11) in the crystalline samples
are different. The bent conformation seems to be more favourable for biological activity than the
extended one. The efflux pump inhibitory properties of the compounds 1–12 were evaluated in the flu-
orescence uptake assay using rhodamine 123 dye in mouse T-lymphoma model in vitro. Their cytotoxic
action was examined, too. All compounds with methyl acetate moiety displayed high potency to inhibit
the MDR efflux pump. The most active compound, methyl 2-(1-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)
butyl)-5,5-diphenylhydantoin-3-yl)acetate (5), tested at 1/10 of verapamil concentration displayed the
9-fold higher P-gp inhibitory action.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
Multidrug resistance (MDR) has become a factor seriously lim-
iting the treatment of various diseases, particularly anticancer
treatment.1–5 The major reason for failure of chemotherapy of can-
cer is the refractory nature of the cells that results from prior expo-
sure to the same or other chemotherapeutic agents. In most of the
tumour cell lines, multidrug resistance is often associated with cel-
lular overexpression of the members of the ATP-binding cassette
(ABC) transporter family, such as P-glycoprotein (P-gp or ABCB1),
which acts as an efflux pump for various anticancer drugs. P-gp
is encoded by the MDR1 (ABCB1) gene and its overexpression in
cancer cells has become a therapeutic target to combat multidrug
resistance.1 Consequently, it is a major challenge for medicinal
science to find a successful method to inhibit P-gp function during
chemotherapy. A main strategy to circumvent the tumour MDR isto co-administer efflux pump inhibitors (EPIs), namely compounds
which are able to block efflux action of MDR drug transporters.1–5
Another challenge is to identify an architecture-mechanism
relationship for the ABC-drug transporters, especially for P-gp.
Thus, discovery and structural analysis of small molecules being
modulators of this transport protein play a significant role in
comprehensive studies on cancer MDR.
Lines of evidence indicate a number of chemical compounds
that modulate P-gp in various assays conditions. Predominantly,
three generations of MDR reversal agents have been widely inves-
tigated.1,3–7 The results obtained ‘are not encouraging’1 and it sug-
gests that a further search for MDR reversal agents with higher
activity and better pharmacological profile are desirable.
On the other hand, derivatives of hydantoin seem to be an inter-
esting lead in pharmacological strategies for overcomingmultidrug
resistance. Recent studies distinctly identified and described a
presence of benzyl-hydantoin binding site in protein transporters
(nucleobase–cation–symport-1 transporters, Mhp, from Microbac-
terium liquefaciens).8,9 Furthermore, several reports have under-
lined hydantoins’ anticancer properties, i.e., an anti-metastatic
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Figure 1. Verapamil and the most potent hydantoin P-gp modulators, BS-1 and JH-63, identified within previous studies.11,12
Table 1
Chemical structures of compounds 1–12
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1 A Me Ph OH 1
2 A Me Ph H 1
3 A Me Ph H 2
4 A Me 2-F-Ph H 2
5 A Me 2,3-DiCl-Ph H 2
6 A H 2-MeO-Ph OH 1
7 A H 2-MeO-Ph H 2
8 B Me 2-Furoyl — —
9 B H 2-Furoyl — —
10 B Me 4-F-Ph — —
11 B Me Ph — —
12 B Me 2-F-Ph — —
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studies,11–14 a series of our representative aromatic (thio)hydan-
toin derivatives were evaluated on their P-glycoprotein inhibition
properties in ABCB1-transfected mouse lymphoma or colon adeno-
carcinoma cells using accumulation assay and/or real-time fluo-
rometry with two dye substrates of ABCB1; a rhodamine 123
and/or ethidium bromide.15 Most of the compounds inhibited the
ABCB1-mediated efflux, particularly, phenylpiperazine derivatives
of 5,5-diphenylhydantoin that contain methyl-substituted (BS-1)
or unsubstituted (JH-63) position 3 (Fig. 1) showed inhibition
potency much higher than that of verapamil, a reference P-gp mod-
ulator,11,12 whereas the 5,5-dimethylhydantoins with aromatic
substituent at position 3 or 5-arylidenoimidazolones demon-
strated much weaker impact on this MDR efflux pump, in the range
of verapamil at most.13,14 Interestingly, there was almost no differ-
ence in very strong P-gp inhibitory action of phenylpiperazine-5,5-
diphenylhydantoins with H or Me at position 3, whereas a shift of
beneficial aromatic moieties from position 5 to position 3 signifi-
cantly decreased the action. This suggested a hypothesis that the
position 3 may not contribute in the P-gp binding whatever is
substituted there.
Taking this into account, we decided to modify the previously
active phenylpiperazine hydantoin structures (BS-1, JH-63) by
introduction of an end-ester group to a substituent at position 3,
and varied arylpiperazine-alkyl fragments at position 1 of hydan-
toin (1–5, Table 1). Additionally, two compounds with not recom-
mended carboxylic acid end at position 3 (6 and 7, Table 1) were
examined to evaluate the contribution of the position 3 in the
P-gp binding. In the next step of the modifications, two phenyl
rings of the 5,5-diphenylhydantoin were bridged to give spirofluo-
rene-hydantoin derivatives (8–12, Table 1). Here, synthesis andcrystallographic studies for selected compounds as well as
biological evaluation for the entire series (1–12) are described.
The structure–activity relationship has been discussed, too.2. Results and discussion
2.1. Chemistry
Syntheses of compounds 1–7 were described elsewhere.15–17
The synthetic route of arylpiperazine derivatives 8–12 was carried
out according to the Scheme 1. Starting from commercially avail-
able 9-fluorenone, Bucherer–Bergs reaction was achieved by the
use of ammonium carbonate and potassium cyanide to afford the
spirofluorene-hydantoin, compound 13. In the following steps, N-
alkylation at position 3 of hydantoin with methyl bromoacetate
(14) and N-alkylation at position 1 (15) with 1,4-dibromobutane
were carried out. The fourth stage was the N-alkylation of an
appropriate arylpiperazine. The compound 9 with the carboxylic
acid terminal fragment was obtained in the last step of the synthe-
sis by hydrolysis of the ester (8) in the presence of potassium
hydroxide (Scheme 1).
2.2. Crystallographic studies
In all studied compounds, the main difference in conformation
of molecules seems to be dependent on the flexible aliphatic chain
which connects the hydantoin and piperazine rings. The conforma-
tions of two derivatives 8 (hydrochloride) and 11 (base) were anal-
ysed by determination of the crystal structures using X-ray
diffraction method.
Figure 2. Atom numbering scheme of 8. Displacement ellipsoids are drawn at the 30% probability level. Hydrogen atoms have been omitted for clarity.
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Scheme 1. The synthesis route for the investigated compounds. Reagents and conditions: (i) Bucherer–Bergs conditions; (ii) K2CO3, TEBA, acetone, reflux; (iii) K2CO3, TEBA,
acetone, rt; (iv) K2CO3, acetone, reflux; (v) 2 h, rt.
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unit cell consists of four molecules. The conformation of 8 is
extended. The molecule is protonated (at N2) by the proton trans-
fer from HCl and makes hydrogen bond with chlorine anion.
The data for the hydrogen bonds are collected in Table 2. The
spirofluorene substituent is almost perpendicular to hydantoinTable 2
Parameters of intermolecular interactions for 8
H  A (Å) D  A (Å) D–H–A () Symmetry code
N2–H2N  Cl 2.12(4) 3.049(3) 163(3)
OW–HWA  O5 2.20 3.046(6) 179.7
OW–HWB  Cl 2.25 3.102(5) 179.6 x + 1/2, y + 1/2, z + 1/2
C26–H26A  OW 2.45 3.255(6) 140.1 x, y + 1, z + 2
C31–H31  OW 2.12 3.005(6) 158.9
C8–H8A  Cl 2.64 3.492(5) 151.9 x, y, z + 2ring. The angle between the planes of these moieties is 86.7. The
carbonyl groups of hydantoin ring and the oxygen atoms of the
ester group are not involved in any hydrogen bonds.
Only one oxygen atom of furoyl group at piperazine ring is
engaged in intermolecular hydrogen bonds (Fig. 3). Furthermore,
a water molecule is involved in hydrogen bonds with the mole-
cules of 8.
The unit cell of 11 consists of four molecules. The molecular
geometry with the atom numbering scheme is shown in Figure 4.
The conformation of molecule is bent in comparison to 8, its
shape without spirofluorene substituent reminds a hairpin. This
difference can be illustrated by the values of torsion angle N1–
C6–C7–C8 169.2 and 54.5 for 8 and 11, respectively. The
spirofluorene substituent is perpendicular to hydantoin ring with
the interplanar bond angle 89.7. In the crystal net, this substituent
is engaged in p–p interactions (Fig. 5). The distance between the
Figure 3. Partial packing view along [100] direction for 8. Dashed lines indicate hydrogen bonds.
Figure 4. Atom numbering scheme of 11. Displacement ellipsoids are drawn at the 30% probability level. Hydrogen atoms have been omitted for clarity.
Figure 5. The interaction of two molecules of 11 showing a p–p stacking. Dashed lines indicate hydrogen bonds.
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all oxygen atoms are involved in intermolecular C–H  O contacts,which parameters are summarized in Table 3. Nitrogen atoms are
not engaged in intermolecular interactions.
Table 3
Parameters of C–H  O interactions for 11
H  A (Å) D  A (Å) D–H–A () Symmetry code
C6–H6A  O1 2.45 3.390(2) 159.4 x, y + 5/2, z + 1/2
C12–H12B  O1 2.47 3.306(2) 141.3
C13–H13B  O2 2.44 3.400(2) 162.6 x, y + 5/2, z  1/2
C18–H18  O4 2.69 3.558(2) 152.0 x, y + 2, z
C21–H21  O4 2.69 3.555(9) 151.8 x, y + 2, z
C28–H28C  O3 2.58 3.298(2) 133.8 x + 1, y + 2, z
C28–H28C  O2 2.46 3.298(2) 133.8 x, y + 5/2, z  1/2
Table 5
Cytotoxic effect of the compounds on sensitive parental (PAR) and resistant (MDR)
mouse T-lymphoma cells
Compound PAR Mean (lM) ± SD MDR Mean (lM) ± SD
1 33 ± 3 67 ± 8
2 40 ± 3 >100
3 13 ± 1 26 ± 2
4 >100 >100
5 18 ± 3 40 ± 6
6 >100 >100
7 >100 >100
8 59 ± 13 63 ± 9
9 >100 >100
10 40 ± 6 56 ± 14
11 53 ± 5 >100
12 58 ± 6 84 ± 2
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2.3.1. Efflux modulating effects
The hydantoin derivatives 1–12 (Table 1) were evaluated for
their efflux modulating effects in cancer cells (mouse T-lymphoma
cell line transfected with the humanMDR1 (ABCB1) gene that codes
for the ABC transporter ABCB1) using a rhodamine 123 accumula-
tion assays.11,18,19 Rhodamine 123 is the substrate for ABCB1. The
percentage of mean fluorescence intensity was calculated for the
treated MDR cells as compared with the untreated cells. A fluores-
cence activity ratio (FAR) was calculated based on the equation
described in the experimental section. All compounds were inves-
tigated at the concentration of 20 lM verapamil and at the 10-fold
lower concentration (2 lM). Both, ester and carboxylic acid, com-
pounds investigated (1–12) were stable under the biological assays
conditions. Results are shown in the Table 4. Among the hydantoin
derivatives evaluated for their inhibition action on the ABCB1
transporter, the compounds 1–5 and 10–12were muchmore effec-
tive than the reference inhibitor verapamil, compound 8 displayed
activities in the range of verapamil and the action of compounds 6,
7 and 9 were significantly lower. Two very active compounds (4
and 5) showed an activity-concentration inversion in the fluores-
cence assay, giving higher FAR value at the lower concentration
(2 lM) with a slight decrease at the higher one (Table 4).
2.3.2. Cytotoxic effects
Compounds were also examined for their cytotoxic action in
both, sensitive (PAR) and resistant (MDR) mouse T-lymphoma cell
lines (Table 5).
The tested hydantoins 1–12 showed low or very low cytotoxic
effects in both cell lines. Especially, compounds 2, 4, 6, 9 and 11
displayed no cytotoxicity in the MDR cell line up the concentration
of 100 lM. The cytotoxic concentration of all compounds (1–12)Table 4
Effects of compounds 1–12 on rhodamine 123 retention by human MDR1 (ABCB1)
gene-transfected mouse lymphoma cells
Compounds FAR (concentration of 2 lM) FAR (concentration of 20 lM)
Verapamil — 17.59
DMSO (2 v/v%) 0.84 —
1 72.64 90.43
2 89.34 116.27
3 77.15 99.82
4 102.74 99.09
5 132.85 98.11
6 0.84 0.86
7 1.00 2.04
8 1.86 24.89
9 0.68 0.69
10 19.40 71.11
11 21.61 70.19
12 35.38 72.04
FAR, fluorescence activity ratio, was calculated using the following equation:
FAR ¼ MDRtreated=MDRcontrolparentaltreated=parentalcontrol :
The inhibition of ABCB1 transporter is evident when FAR > 1.11 Since the treatment
had no effect on the parental cells (PAR) lacking the overexpressed ABCB1 system,
the intensity of fluorescence did not change in the treated cells compared to the
control ones, for this reason the denominator was considered as 1.was much higher than their lower concentration (2 lM) in the rho-
damine 123 accumulation assay. Only two compounds, 3 and 5,
demonstrated cytotoxic properties in the range of the higher con-
centration (20 lM) in the accumulation assay (Tables 4 and 5). The
relatively higher cytotoxic action in the PAR cells than that of cell
lines with overexpression of ABCB1 was found for all compounds
that were very potent in the accumulation assays (1–3, 5,
10–12), what confirmed the P-gp substrate properties of the
compounds (Table 5).
2.4. Structure–activity relationship discussion
The obtained results allow us to perform some structure–
activity relationship analysis. The highest efflux inhibitory action
was found for the 2,3-dichlorophenyl derivative of the ester
5,5-diphenylhydantoin (5), which displayed 9-fold higher FAR
value at the lower concentration (2 lM) than that of verapamil
at the 10-fold higher concentration (20 lM). The very high activity
was also observed for the ester 5,5-diphenylhydantoins with
2-fluorophenyl (4) and unsubstituted phenyl at piperazine (2, 3
and 1). Although the spirofluorenehydantoin compounds (8–12)
displayed some decrease in the dye efflux inhibitory action in com-
parison to the corresponding 5,5-diphenylhydantoins (1–7), they
represent similar trends in the structure–activity relationship.
Thus, all compounds possessing more hydrophobic phenylpiper-
azine terminal fragment at position 1 of hydantoin and the methyl
ester end at position 3 are very potent ABCB1 modulators. The
furoyl derivative with ester at position 3 (8) was also an active
inhibitor but in the range of verapamil, while it lost the inhibitory
potency when the ester group was converted into carboxyl one (9).
Likewise, the compounds 6 and 7 also with the carboxyl terminal
fragment had no activity. The examination of the compounds with
carboxyl end at position 3 indicates that the N3-side of hydantoin
is not hidden from interactions with P-gp. The ester fragment at
position 3 is responsible for the high potency (1–5, 10–12),
whereas the deprotected acid group (6, 7 and 9) caused a very
strong reduction of the inhibitory action. However, our previous
results13 indicate that introduction of favourable aromatic moieties
at 3-hydantoin is not able to maintain the high P-gp inhibitory
activities of phenylpiperazine hydantoins when they are deprived
of aromatic fragments at position 5. This suggests that aromatic
(phenyl) substituents at position 5 are crucial for the intensive
P-gp inhibitory action.
The position of the hydrophobic substituent at the phenylpiper-
azine phenyl ring seems to be also important as the ortho-fluoro
derivative was a bit more beneficial than the para one. Some
decrease in activity is noted if the phenylpiperazine phenyl sub-
stituent is replaced with the furoyl one (8). However, only an
exchange of ester N3-terminal moiety for the aforementioned car-
boxyl termination (9) significantly reduces the activity. Some role
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can be seen, as well. The introduction of the hydroxyl group into
the linker reduced activity of compounds 1 and 6 in comparison
to the corresponding compounds with unbranched linkers (2 and
7). The results indicated that any decrease in hydrophobicity of
the 5-aromatic arylpiperazine hydantoin compounds (1–12),
observed at both, N3 and N1 terminal fragments, is disadvanta-
geous for the modulating action on ABCB1.
As far as cytotoxic studies concern, there is no clear structure–
activity relationship. In general, the cytotoxic action of the series of
hydantoin compounds was rather low, especially in the case of
compounds with the carboxylic terminal fragment (6, 7, and 9).
However, it is not a rule as the 2-fluorophenylpiperazine ester
(4) was also devoid of cytotoxicity in the same concentration
range, whereas both structural analogues of the compound 4, the
phenyl (3) and the 2,3-dichlorophenyl (5) ones, were the most
cytotoxic in the whole series.
Crystallographic studies show that the extended conformation
of the main motif in investigated molecules is less preferred for
better inhibitors of efflux modulating effects in cancer cells (8).
Furthermore, this molecule does not use all potential groups,
which are able to form hydrogen bonds, to intermolecular interac-
tions. The molecule of 11 has a bent conformation andmore groups
are involved in intermolecular hydrogen bonds. This molecule
shows much better properties as inhibitor of efflux modulating
effects in cancer cells.3. Conclusion
The studies allowed us to identify a new group of very potent P-
gp modulators in the cancer cells and to have an insight in their
structural properties. On the basis of the results obtained, com-
pounds with ester substituents at position 3 can be considered as
very promising cancer MDR efflux pump inhibitors with a potential
therapeutic future as their ABCB1 blocking action is much more
potent than that of reference modulator, verapamil, and their
cytotoxic effects are negligible.4. Experimental
4.1. Chemical synthesis
1H NMR spectra were recorded on a Varian Mercury-VX
300 MHz PFG instrument in DMSO-d6 at ambient temperature
using the solvent signal as an internal standard: the values of the
chemical shifts are expressed in d values (ppm) and the coupling
constants (J) in Hz. Mass spectra were recorded on a UPLC–MS/
MS system consisted of a Waters ACQUITY UPLC (Waters Corpo-
ration, Milford, MA, USA) coupled to a Waters TQD mass spectrom-
eter (electrospray ionization mode ESI-tandem quadrupole). The
UPLC/MS purity of all the final compounds was confirmed to be
higher than 95%. Retention times (tR) are given in minutes. Thin-
layer chromatography was performed on pre-coated Merck silica
gel 60 F254 aluminium sheets, the used solvent systems were (I)
CH2Cl2/MeOH 19:1, (II) toluene/acetone 40:3, (III) toluene/ace-
tone/methanol 15:5:1, (IV) CHCl3/i-PrOH/NH3aq 9:11:3. Melting
points were determined using Mel-Temp II apparatus and are
uncorrected. The reactions at a fixed temperature were carried
out using a magnetic stirrer with a contact thermometer Heidolph
MR 2001.
4.1.1. Synthesis of spiro(fluorene-9,50-imidazolidin)-20,40-dione
(13)
While stirring, a solution of potassium cyanide (7.88 g) in water
(160 ml) was introduced into a mixture of 9-fluorenone (18.2 g,0.1 mol), ammonium carbonate (38 g), ethanol (160 ml). The mix-
ture was stirred for 56 h at 58 C, according to a progress controlled
by TLC (I). After 56 h the temperature was increased to 88 C and
the stirring was continued for additional 4 h. The reaction mixture
was cooled and acidified with concentrated hydrochloric acid to
pH of 3. The precipitate was filtered off and crystallized from etha-
nol to give yellow crystals of 13. Yield 68%; mp: 304–306 C; TLC:
Rf (I): 0.32. 1H NMR (DMSO-d6, ppm) d: 7.31–7.39 (m, 2H, H2,7–Ar),
7.45–7.50 (m, 4H, H1,3,6,8–Ar), 7.86–7.89 (d def., 2H, H4,5–Ar), 8.57
(s, 1H, H-N1), 11.22 (br s, 1H, H-N3). LC–MS: purity 96.73%,
tR = 4.41, (ESI) m/z: calculated for C15H10N2O2 [M+H]+: 251.25,
found: 251.08.
4.1.2. Synthesis of methyl 2-(spiro(fluorene-9,50-imidazolidin)-
20,40-dione-30-yl)acetate (14)
Spiro(fluorene-9,50-imidazolidine)-20,40-dione 13 (0.06 mol,
15 g), potassium carbonate (24 g), TEBA (1.8 g) in acetone
(300 ml) were stirred under reflux for 30 min. Then a solution of
methyl bromoacetate (0.06 mole, 9.2 g) in acetone (60 ml) was
added and the mixture was maintained at reflux for 6 h, according
to a progress controlled by TLC (II). The inorganic precipitate was
filtered off. The filtrate, after evaporation of solvents, was crystal-
lized from ethanol to give white crystals of 14. Yield 54%; mp:
171–173 C; TLC: Rf (II): 0.27. 1H NMR (DMSO-d6, ppm): d 3.73
(s, 3H, OCH3), 4.40 (s, 2H, CH2–N3), 7.32–7.40 (m, 2H, H2,7–Ar),
7.44–7.55 (m, 4H, H1,3,6,8–Ar), 7.86–7.90 (d def., 2H, H4,5–Ar),
9.08 (s, 1H, NH). LC–MS: purity 95.11%, tR = 5.46, (ESI) m/z: calcu-
lated for C18H14N2O4 [M+H]+: 323.10, found: 323.12.
4.1.3. Synthesis of methyl 2-(10-(4-bromobutyl)-spiro(fluorene-
9,50-imidazolidin)-20,40-dione-30-yl)acetate (15)
Methyl 2-(spiro(fluorene-9,50-imidazolidine)-20,40-dione-30-yl)
acetate 14 (0.025 mol, 8.05 g), potassium carbonate (10 g), TEBA
(0.755 g) in acetone (50 ml) were stirred at room temperature for
30 min. Then, a solution of 1,4-dibromobutane (0.03 mmol,
6.42 g) in acetone (30 ml) was added and stirred at room temper-
ature for 142 h, according to a progress controlled by TLC (II). The
inorganic precipitate was filtered off. The filtrate, after evaporation
of solvents, was crystallized from ethanol to give white powder of
15. Yield 38%; mp: 144–145 C; TLC: Rf (II): 0.48. 1H NMR (DMSO-
d6, ppm): d 1.06–1.15 (qudef, 2H, CH2–CH2–Br), 1.52–1.62 (qu,
J = 7.1 Hz, 2H, CH2CH2–N1), 2.89 (t, J = 7.1 Hz, 2H, N1–CH2), 3.23
(t, J = 6.5 Hz, 2H, CH2–Br), 3.73 (s, 3H, OCH3), 4.40 (s, 2H, CH2–
N3), 7.40–7.42 (m, 2H, H2,7–Ar), 7.47–7.56 (m, 4H, H1,3,6,8–Ar),
7.93–7.95 (ddef, 2H, H4,5–Ar). LC–MS: purity 95.23%, tR = 7.60,
(ESI) m/z: calculated for C22H21BrN2O4 [M+H]+: 458.32, found:
459.03.
4.1.4. General procedure for synthesis of arylpiperazine deriva-
tives 8, 10–12
Commercially available phenylpiperazine (3–5 mmol), K2CO3
(1.2–2.0 g) and acetone (10–25 ml) were stirred for 30 min. Then
a solution of methyl 2-(10-(4-bromobutyl)-spiro(fluorene-9,50-imi-
dazolidine)-20,40-dione-30-yl)acetate 15 (3–5 mmol, 1.37–2.29 g) in
acetone (12–15 ml) was added. The mixture was maintained at
reflux for 8 h, left at room temperature for 15 h. The precipitate
was filtrated off. The filtrate was concentrated to constant weight.
The crude residue was purified to give a precipitate of the final
compound (8, 10–12).
4.1.4.1. Methyl 2-(10-(4-(4-(2-furoyl)piperazin-1-yl)butyl)-spiro
(fluorene-9,50-imidazolidine)-20,40-dione-30-yl)acetate hydro-
chloride (8). 2-Furoylpiperazine (3 mmol, 0.54 g), K2CO3
(1.2 g) in acetone (10 ml) and methyl 2-(10-(4-bromobutyl)-spiro
(fluorene-9,50-imidazolidine)-20,40-dione-30-yl)acetate 15 (3 mmol,
1.37 g) in acetone (12 ml) were used. The crude residue was
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10:1, v/v). The purest product fractions were concentrated, dis-
solved in EtOH and saturated with gaseous HCl. The precipitate
was filtrated off and dried to give white powder of hydrochloride
of 8. Yield 32%; mp: 193–194 C; TLC: Rf (III): 0.30. 1H NMR
(DMSO-d6, ppm): d 0.99–1.06 (m, 2H, CH2CH2–piperazine), 1.46
(br s, 2H, CH2CH2–N1), 2.80 (br s, 2H, CH2–piperazine), 2.92 (tdef,
J = 7.4 Hz, 4H, H2,6-piperazine), 3.29–3.43 (m, 6H, CH2–N1,
H3,5-piperazine), 3.73 (s, 3H, OCH3), 4.41 (s, 2H, CH2–N3), 6.64 (tdef,
J = 1.8 Hz, 1H, H4–furan), 7.07 (d, J = 3.1 Hz, 1H, H5–furan),
7.39–7.44 (m, 2H, H2,7–Ar), 7.50–7.57 (m, 4H, H1,3,6,8–Ar),
7.85 (d, J = 1.0 Hz, 1H, H3–furan), 7.95 (d, J = 7.4 Hz, 2H, H4,5–Ar),
10.31 (br s, 1H, NH+). LC–MS: purity 96.16%, tR = 4.56, (ESI) m/z:
calculated for C31H33N4O6 [M+H]+: 557.24, found: 557.38.
4.1.4.2. Methyl 2-(10-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-
spiro(fluorene-9,50-imidazolidin)-20,40-dione-30-yl)acetate (10).
4-(4-Fluorphenyl)piperazine (5 mmol, 0.9 g), K2CO3 (2.0 g) in ace-
tone (15 ml) and methyl 2-(10-(4-bromobutyl)-spiro(fluorene-
9,50-imidazolidine)-20,40-dione-30-yl)acetate 15 (5 mmol, 2.29 g)
in acetone (15 ml) were used. The crude residue of 10 was purified
by column chromatography. The individual fractions were eluted
using the following pure solvents: methylene chloride and metha-
nol. The obtained product fractions were concentrated. A sticky
residue was obtained and crystallized from methanol to give white
crystals of 10. Yield 25%; mp: 142–143 C; TLC: Rf (III): 0.66. 1H
NMR (DMSO-d6, ppm): d 1.00 (qu, J = 7.05 Hz, 2H, CH2CH2–piper-
azine), 1.19 (t, J = 6.2 Hz, 2H, CH2CH2–N1), 1.95 (t, J = 7.2 Hz, 2H,
CH2–piperazine), 2.25 (t, J = 5.0 Hz, 4H, H2,6-piperazine), 2.90–
2.94 (m, 6H, CH2–N1 and H3,5-piperazine), 3.73 (s, 3H, OCH3),
4.40 (s, 2H, CH2–N3), 6.86–6.90 (m, 2H, H2,6-PhPp), 7.01 (t,
J = 6.1 Hz, 2H, H3,5-PhPp), 7.37–7.41 (m, 2H, H2,7–Ar), 7.47–7.54
(m, 4H, H1,3,6,8–Ar), 7.93 (d, J = 7.4 Hz, 2H, H4,5–Ar). LC–MS: purity
96.15%, tR = 5.18, (ESI) m/z: calculated for C32H33FN4O4 [M+H]+:
557.25, found: 557.44.
4.1.4.3. Methyl 2-(10-(4-(4-phenylpiperazin-1-yl)butyl)-spiro
(fluorene-9,50-imidazolidine)-20,40-dione-30-yl)acetate (11).
N-Phenylpiperazine (4 mmol, 0.64 g), K2CO3 (1.6 g) in acetone
(25 ml) and methyl 2-(10-(4-bromobutyl)-spiro(fluorene-9,50-imi-
dazolidine)-20,40-dione-30-yl)acetate 15 (4 mmol, 1.83 g) in acetone
(12 ml) were used. The crude residue was crystallized with metha-
nol to give a white powder of 11. Yield 37%; mp: 117–118 C; TLC:
Rf (III): 0.69. 1H NMR (DMSO-d6, ppm): d 1.00 (t, J = 7.2 Hz, 2H, CH2-
CH2–piperazine), 1.17–1.22 (m, 2H, CH2CH2–N1), 1.96 (t, J = 2H,
CH2–piperazine), 2.26 (t, J = 1.8 Hz, 4H, H2,6-piperazine), 2.89–
2.97 (m, 6H, CH2–N1, H3,5-piperazine), 3.31 (s, 3H, OCH3), 4.40 (s,
2H, CH2–N3), 6.74 (t, J = 5.6 Hz, 1H, H4–PhPp), 6.87 (d, 2H,
J = 4.6 Hz, H2,6-PhPp). 7.18 (t, J = 5.6 Hz, 2H, H3,5-PhPp), 7.39–7.42
(m, 2H, H2,7–Ar), 7.47–7.54 (m, 4H, H1,3,6,8–Ar), 7.93 (d, 2H,
J = 7.7 Hz, H4,5–Ar). LC–MS: purity 95.18%, tR = 5.32, (ESI) m/z:
calculated for C32H34N4O4 [M+H]+: 539.26, found: 539.43.
4.1.4.4. Methyl 2-(10-(4-(4-(2-fluorophenyl)piperazin-1-yl)butyl)-
spiro(fluorene-9,50-imidazolidine)-20,40-dione-30-yl)acetate (12).
4-(2-Fluorphenyl)piperazine (4 mmol, 0.72 g), K2CO3 (1.6 g) in
acetone (25 ml) and methyl 2-(10-(4-bromobutyl)-spiro(fluorene-
9,50-imidazolidine)-20,40-dione-30-yl)acetate 15 (4 mmol, 1.83 g) in
acetone (12 ml) were used. The crude residue was crystallized with
methanol to give white powder of 12. Yield 82%; mp 99–101 C;
TLC: Rf (III): 0.65 1H NMR (DMSO-d6, ppm): d 1.00 (t, J = 6.4 Hz,
2H, CH2CH2–Pp), 1.19 (t, J = 6.2 Hz, 2H, CH2CH2–N1), 1.97 (t,
J = 7.2 Hz, 2H, CH2–Pp), 2.28 (br s, 4H, H2,6-Pp), 2.83–2.92 (m, 6H,
CH2–N1, H3,5-Pp), 3.73 (s, 3H, OCH3), 4.40 (s, 2H, CH2–N3), 6.94–
6.97 (m, 2H, H4,6-PhPp), 7.06–7.12 (m, 2H, H3,5-PhPp), 7.37–7.42
(m, 2H, H2,7–Ar), 7.47–7.55 (m, 4H, H1,3,6,8–Ar), 7.94 (d, J = 3.8 Hz,2H, H4,5–Ar). LC–MS: purity 95.17%, tR = 5.34, (ESI) m/z: calculated
for C32H33FN4O4 [M+H]+: 557.25, found: 557.44.
4.1.4.5. Synthesis of 2-(10-(4-(4-(2-furoyl)piperazin-1-yl)butyl)-
spiro(fluorene-9,50-imidazolidine)-20,40-dione-30-yl)acetic acid
(9). Methyl 2-(10-(4-(4-(2-furoyl)piperazin-1-yl)butyl)-spiro
(fluorene-9,50-imidazolidine)-20,40-dione-30-yl)acetate 8 (0.54
mmol, 0.3 g), 50% EtOH (4 ml), KOH (0.2 g) was stirred for 2 h.
Sticky substance was obtained and left in lower temperature to
crystallize. The precipitate was filtrated off and dried to give
white powder of 9. Yield 80%; mp: 182–183 C; TLC: Rf (IV): 0.15.
1H NMR (DMSO-d6, ppm): d 0.99 (t, J = 7.7 Hz, 2H, CH2–piperazine),
1.38 (br s, 2H, CH2CH2–N1), 2.91 (t, J = 7.2 Hz, 6H, CH2–pierazine
and H2,6–piperazine), 3.32–3.43 (m, 6H, CH2–N1 and
H3,5–piperazine), 4.27 (s, 2H, CH2–N3), 6.62–6.64 (dd, J = 5.4 Hz,
1H, H4–furan), 7.04 (d, J = 3.3 Hz, 1H, H5–furan), 7.38–7.42
(m, 2H, H2,7–Ar), 7.49–7.56 (m, 4H, H1,3,6,8–Ar), 7.85 (d, J = 0.8 Hz,
1H, H3–furan), 7.95 (d, J = 6.4 Hz, 2H, H4,5–Ar). LC–MS: purity
98.11%, tR = 3.98, (ESI) m/z: calculated for C30H30N4O6 [M+H]+:
543.22, found: 543.42.
4.2. X-ray crystal structure analysis
Crystals of both compounds were obtained at room tempera-
ture from a solution of propan-2-ol and water by slow evaporation
of the solvent. Colourless crystals appeared within three months.
Data for single crystals were collected using the Oxford Diffraction
SuperNova four circle diffractometer, equipped with the Mo
(0.71069 Å) Ka radiation source, graphite monochromator. Posi-
tions of all non-hydrogen atoms were determined by direct meth-
ods using SIR-97.20 All non-hydrogen atoms were refined
anisotropically using weighted full-matrix least-squares on F2.
Refinement and further calculations were carried out using
SHELXL-97.21 ORTEP22 and MERCURY23 programs were used for
molecular graphics.
8: [(C31H33N4O6)+Cl]H2O, Mr = 611.08, crystal size
0.46  0.43  0.19 mm3, monoclinic, space group P21/n,
a = 11.891(5) Å, b = 13.382(5) Å, c = 18.980(5) Å, b = 100.512(5),
V = 2970(2) Å3, Z = 4, T = 293(2) K, 40796 reflections collected,
7210 independent reflections (R(int) = 0.0265), R1 = 0.0734,
wR2 = 0.2067 (I > 2sigma(I)), R1 = 0.0986, wR2 = 0.2292 (all data).
11: C32H34N4O4, Mr = 538.63, crystal size 0.46  0.25 
0.14 mm3, monoclinic, space group P21/c, a = 18.7592(5) Å,
b = 11.2153(3) Å, c = 13.8436(4) Å, b = 107.031(3), V = 2784.8(1) Å3,
Z = 4, T = 120(2) K, 39045 reflections collected, 6661 independent
reflections (R(int) = 0.0560), R1 = 0.0483, wR2 = 0.1155 (I > 2sigma
(I)), R1 = 0.0667, wR2 = 0.1279 (all data).
CCDC 1444020 and 1444021 contain the supplementary crys-
tallographic data for compounds 11 and 8, respectively. These data
can be obtained free of charge from The Cambridge Crystallo-
graphic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
4.3. Biological assays
4.3.1. Cell lines
The L5178 mouse T-cell lymphoma cells (PAR) (ECACC Cat. No.
87111908, obtained from FDA, Silver Spring, MD, USA) were trans-
fected with pHa MDR1/A retrovirus, as previously described by
Cornwell et al.18 ABCB1-expressing cell line L5178Y (MDR) was
selected by culturing the infected cells with colchicine. L5178
(parent) mouse T-cell lymphoma cells and the L5178Y human
ABCB1-transfected subline were cultured in McCoy’s 5A medium
supplemented with 10% heat inactivated horse serum, 200 mM
L-glutamine, and penicillin–streptomycin mixture in 100 U/l and
10 mg/l concentration, respectively.
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The effects of increasing concentrations of the drugs alone on
cell growth were tested in 96-well flat-bottomed microtiter plates.
The compounds were diluted in a volume of 100 ll medium. Then,
2  104 L5178 mouse T-lymphoma cells (PAR or MDR) in 100 ll of
medium, respectively, were added to each well, with the exception
of the medium control wells. The culture plates were further incu-
bated at 37 C for 24 h; at the end of the incubation period, 20 ll of
MTT solution (from a 5 mg/ml stock) was added to each well. After
incubation at 37 C for 4 h, 100 ll of SDS solution (10% in 0.01 M
HCI) was added to each well and the plates were further incubated
overnight at 37 C overnight. The cell growth was determined by
measuring the OD at 540 nm (ref. 630 nm) with Multiscan EX
ELISA reader (Thermo Labsystems, Cheshire, WA, USA).
4.3.3. Fluorescence uptake assay
The cell number of L5178 MDR and L5178Y PAR cell lines was
adjusted to 2  106 cells/ml, re-suspended in serum-free McCoy’s
5A medium and distributed in 0.5 ml aliquots into Eppendorf cen-
trifuge tubes. The tested compounds were added at a final concen-
tration of 2 and 20 lM, and the samples were incubated for 10 min
at room temperature. Verapamil was applied as positive control at
20 lM. DMSO was added to the negative control tubes at the same
volume that had been used for the tested compounds. No activity
of DMSO was observed. Next, 10 ll (5.2 lM final concentration)
of the fluorochrome and ABCB1 substrate rhodamine 123 was
added to the samples and the cells were incubated for a further
20 min at 37 C, washed twice and re-suspended in 0.5 ml PBS
for analysis. The fluorescence of the cell population was measured
with a PartecCyFlow flow cytometer (Partec, Münster, Germany).
The percentage of mean fluorescence intensity was calculated for
the treated MDR cells as compared with the untreated cells. A flu-
orescence activity ratio (FAR) was calculated based on the follow-
ing equation on the basis of the measured fluorescence values:
FAR ¼ MDRtreated=MDRcontrol
parentaltreated=parentalcontrolAcknowledgments
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